| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
1 Department of Environmental Sciences and Engineering, and 2 Curriculum in Toxicology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; 3 College of Arts and Sciences, University of Virginia, Charlottesville, Virginia; 4 Research Reactor Institute, Kyoto University, Kumatori, Japan; 5 Department of Radiation Genetics Graduate School of Medicine, Kyoto, Japan; 6 GSF-National Research Center for Environment and Health, Institute for Molecular Radiobiology, Neuherberg-Munich, Germany; 7 Beatson Institute for Cancer Research, Glasgow, United Kingdom; 8 Medical Research Council Laboratory of Molecular Biology, Division of Protein and Nucleic Acid Chemistry, Cambridge, United Kingdom; 9 Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois; and 10 Department of Human Genetics, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
Requests for reprints: Jun Nakamura, Department of Environmental Sciences and Engineering, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599. Phone: 919-966-6140; Fax: 919-966-6123; E-mail: ynakamur{at}email.unc.edu.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
Fanconi anemia is characterized by developmental abnormalities, susceptibility to certain cancers, and sensitivity to DNA-DNA crosslinking agents (6). At least 13 FANC complementation groups (A, B, C, D1, D2, E, F, G, I, J, L, M, N) have been identified (6). These proteins interact in a common pathway that activates FANCD2 via monoubiquitination (6). Upon recognition of a stalled replication fork, for instance, by the nuclear E3 monoubiquitin ligase core complex, activated FANCD2 is targeted to BRCA1 nuclear foci where it regulates DNA repair by possibly homologous recombination and translesion synthesis (6). DT40 cells and their isogenic mutants have predominantly been used to investigate the function of various gene products (7). In the present study, we assessed the DNA damage response to formaldehyde by the reverse genetic approach using the DT40 cell model system and isogenic human cancer cells deficient in the FANC pathway.
| Materials and Methods |
|---|
|
|
|---|
Cell lines and cell culture. All DT40 mutants were derived from isogenic DT40 parent cell lines (Supplementary Table S1). The DT40 cells and their mutants were cultured as previously reported (8). Parental colorectal cancer cell lines (RKO) cells and isogenic clones harboring an engineered disruption of FANCC or FANCG (9) were cultured in a humidified 5% CO2 atmosphere at 37°C. The medium consisted of RPMI 1640 cell culture medium containing 10% FBS (heat inactivated), 100 mg/mL penicillin, and 100 mg/mL streptomycin.
Cell survival assay. For DT40 cells and their mutants, suspended cells (
600 cells per 250 µL per well) were seeded into 24-well plates, exposed to formaldehyde (and other aldehydes), and allowed to divide for
10 cycles. The formaldehyde used was 37% aqueous and was serially diluted in sterile 1x PBS (Life Technologies) to obtain the appropriate concentrations in the plates. All formaldehyde dilutions were made fresh and kept on ice. (Initially, a colony formation assay was attempted, but discontinued, as it seemed formaldehyde reacted adversely with the methylcellulose semisolid medium). After cultivation, cell viability was determined by the XTT assay (10). For RKO cells and their isogenic cells deficient in FANCC or FANCG, the adhesive cells (
600 cells per 250 µL per well) were seeded into 24-well plates and cultivated for 2 days before treatment. After changing to fresh medium, the cells were exposed to formaldehyde and allowed to divide for 7 days. The medium was replenished at 4 days after treatment. The survival rates were determined as described above.
Determination of intracellular total GSH. Total GSH levels were measured according to the manufacturer's directions using a commercially available kit.
Statistical analysis. Survival data were log-transformed giving approximate normality. Analysis of covariance (ANCOVA) was used to test for mean intercept differences and differences in the slopes of the linear dose-response curves between wild-type and a series of mutant cells.
| Results and Discussion |
|---|
|
|
|---|
|
|
|
|
Role of translesion DNA synthesis and cell cycle checkpoint pathways in the repair of DNA damage induced by formaldehyde. In the DT40 cell model system, REV1-deficient, REV3-deficient, and RAD18-deficient cells have been reported to be hypersensitive to various DNA-DNA intercrosslinking agents, including cisplatin and mitomycin C (15). To determine the role of translesion synthesis in the repair of DNA damage induced by formaldehyde, we exposed DT40 and DT40 cells deficient in REV1, REV3, and RAD18 along with POL
to formaldehyde. For the REV1, REV3, and RAD18 mutants, our results show good agreement with the intercrosslinking study, whereas POL
mutants were only marginally sensitive to formaldehyde (Fig. 1A and B; Supplementary Fig. S1E). Proliferating cell nuclear antigen (PCNA) has been reported to be partly ubiquitinated in a RAD18-dependent manner, and this monoubiquitination of PCNA is necessary for carrying out translesion synthesis by polymerase
in yeasts (16). In addition, it has been proposed that ATR/CHK1 signaling is required for RAD18-mediated PCNA monoubiquitination against DNA damage induced by benzo(a)pyrene dihydrodiol epoxide (17). To further characterize the DNA damage response to formaldehyde, we exposed formaldehyde to cells deficient in the S-phase cell cycle components ATM or CHK1. Formaldehyde sensitivity in these cells was similar to parental cells (Fig. 1A and B; Supplementary Fig. S1F). These results suggest that neither the ATM nor CHK1 pathway participate in the DNA damage response to formaldehyde-induced DNA damage.
Role of FANCD2 in the repair of DNA damage induced by endogenously existing aldehydes other than formaldehyde. Using DT40 cells deficient in FANCD2, the most sensitive cell line to formaldehyde, we addressed whether other major endogenously existing aldehydes cause similar hypersensitivity to FANCD2 cells. Among the endogenously existing aldehydes potentially capable of inducing DPCs (18), acetaldehyde caused hypersensitivity in FANCD2 cells at millimolar levels (Fig. 2A
). Methylglyoxal (Fig. 2B), glyoxal (data not shown), acrolein, and crotonaldehyde (Fig. 2C and D) showed no hypersensitivity in FANCD2 cells (Fig. 2B–D). These results suggest that the FANC pathway may be essential to counteract DPCs induced by aliphatic short monoaldehydes, but not DPCs caused by either aliphatic dicarbonyl compounds or
,β-unsaturated aldehydes. Another possibility is that either
,β-unsaturated aldehydes or aliphatic dicarbonyl compounds may more efficiently introduce other types of deleterious DNA lesions, such as exocyclic base adducts or oxidative base lesions.
Endogenous DPC-inducing agents and Fanconi anemia. Fanconi anemia, a rare disease with heterozygosity existing at a frequency of
0.4% of the population (19), is an inherited disorder associated with progressive bone marrow failure and predisposition to malignant leukemia and solid tumors (6). It has been well documented that cells from Fanconi anemia patients are hypersensitive to DNA interstrand crosslinking agents (6), with an associated increase in chromosomal breakage. We know, however, of no report that has described a condition whereby endogenous reactive agents, such as formaldehyde, have induced DPCs with the further induction of toxicity in cells deficient in the FANC pathway. It has been reported that endogenous formaldehyde in human plasma is detectable at concentrations ranging from 13 to 97 µmol/L (3, 4). The two most sensitive DT40 mutants are FANCD1 (BRCA2)–deficient and FANCD2-deficient cells, which showed hypersensitivity to formaldehyde at concentrations between 10 and 15 µmol/L. This observation raises a question about the relevance of data derived from the DT40 model system to the human cellular response to formaldehyde. Therefore, we exposed RKO cells and their isogenic cells disrupted in FANCC or FANCG. The human cells deficient in either FANCC or FANCG were hypersensitive to formaldehyde at concentrations 20 µmol/L or higher (FANCC) or 38 µmol/L or higher (FANCG; Fig. 3
). These results indicate that the FANC/BRCA pathway plays a critical function in not only DT40 cells, but in human cells. Therefore, we currently hypothesize that endogenous formaldehyde induces DPCs and plays a critical role in the initiation of progressive bone marrow failure or predisposition to malignant tumors in Fanconi anemia patients.
Possible DNA repair pathways for DPCs induced by formaldehyde. It is widely accepted that formaldehyde predominantly introduces DPCs in cells. The DPC formation is believed to be related to formaldehyde-induced cancer in animals and humans; however, little information is available in terms of the DNA damage response to formaldehyde. Interestingly, we recognized that the DNA damage responses to formaldehyde in the DT40 cell model system were similar to those of cisplatin (15). For example, survival of isogenic DT40 mutants to cisplatin is in the following order: REV3 > FANCC > RAD18 > XRCC2 > XRCC3 > PARP1 > RAD54 > BRCA1 > XPA = ATM > BRCA2 = MSH3 > parental DT40 cells. Because both DNA-DNA crosslinks and DPCs have the potential to cause stalled DNA replication forks and may introduce double-strand breaks, hypersensitivity of homologous recombination–deficient cells to formaldehyde is likely due to DPCs. Furthermore, cisplatin induces DPCs in addition to interstrand or intrastrand crosslinks. The similarity of the DNA damage response in DT40 mutants to cisplatin and formaldehyde also raised the possibility that DPCs caused by cisplatin may have a role in the hypersensitivity of DT40 cells deficient in the FANC/BRCA and homologous recombination pathways. We also found hypersensitivity of PARP1-deficient DT40 cells to formaldehyde. Interestingly, PARP1 also inhibits homologous recombination from interference by Ku and ligase IV in DT40 cells (20). This report, combined with our results, suggests that without precise regulation of homologous recombination in the absence of PARP1, the homologous recombination repair pathway for the repair of double-strand breaks induced by DPCs may not efficiently restore the integrity of genomic DNA. Although XPA mutants are more resistant to formaldehyde compared with homologous recombination–deficient cells (a characteristic shared with cisplatin; ref. 15), XPA-deficient cells were moderately hypersensitive to formaldehyde, suggesting a reasonable role for NER in the elimination of DNA damage caused by formaldehyde. Figure 4 shows a possible DNA repair pathway to counteract DPCs induced by formaldehyde. In the error-free DPC excision process, formaldehyde-induced DPCs could be first degraded to DNA–amino acid crosslinks (DAC) by a cellular proteasome. The NER pathway may recognize and eliminate the DACs followed by DNA repair synthesis (11, 12, 14). In contrast, error-prone DPC excision processes could exist to tolerate formaldehyde-induced damage. After degradation of DPCs to DACs but before initiation of excision repair, DNA replication may start and translesion synthesis DNA polymerases may by-pass and extend DNA synthesis past the DACs. After DNA replication, the NER pathway may recognize and eliminate the DACs followed by DNA repair synthesis. Because homologous recombination–deficient cells are hypersensitive to formaldehyde, the requirement for homologous recombination repair for uncoupling of initiation of DNA replication and excision repair processes can be hypothesized. The NER pathway recognizes and eliminates DACs. Before the completion of excision repair, DNA replication could begin and lead to the formation of DNA double-strand breaks with subsequent repair by a homologous recombination–dependent pathway. Another possibility is that DPCs formed during DNA replication cause stalled DNA replication forks, followed by the formation of DNA double-strand breaks. The homologous recombination–dependent pathway could then repair these DNA double-strand breaks.
| Acknowledgments |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Dr. Tadayoshi Bessho, Dr. Elizabeth Fryar Tita, Dr. Nadia Georgieva, Dr. Scott Blutman, and Brian F. Pachkowski for critically reading the manuscript and Dr. Scott E. Kern for providing isogenic RKO cells.
| Footnotes |
|---|
Current address for M. Takata: Radiation Biology Center, Kyoto University, Kyoto, Japan, and M. Yamazoe: Wakayama Medical University, School of Medicine, Wakayama, Japan.
Received 8/ 7/07. Revised 9/24/07. Accepted 10/11/07.
| References |
|---|
|
|
|---|
in repair of oxidation DNA damage in chicken DT40 cells. DNA Repair (Amst) 2007;6:869–75.[CrossRef][Medline]
and is required for recovery from S-Phase checkpoint-mediated arrest. Mol Cell Biol 2006;26:3527–40.This article has been cited by other articles:
![]() |
T. Nakano, A. Katafuchi, M. Matsubara, H. Terato, T. Tsuboi, T. Masuda, T. Tatsumoto, S. P. Pack, K. Makino, D. L. Croteau, et al. Homologous Recombination but Not Nucleotide Excision Repair Plays a Pivotal Role in Tolerance of DNA-Protein Cross-links in Mammalian Cells J. Biol. Chem., October 2, 2009; 284(40): 27065 - 27076. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. H. Salem, T. Nakano, M. Takuwa, N. Matoba, T. Tsuboi, H. Terato, K. Yamamoto, M. Yamada, T. Nohmi, and H. Ide Genetic Analysis of Repair and Damage Tolerance Mechanisms for DNA-Protein Cross-Links in Escherichia coli J. Bacteriol., September 15, 2009; 191(18): 5657 - 5668. [Abstract] [Full Text] [PDF] |
||||
![]() |
S MASUNAGA, K TANO, M WATANABE, G KASHINO, M SUZUKI, Y KINASHI, K ONO, and J NAKAMURA Evaluation of the potential of hexamethylenetetramine, compared with tirapazamine, as a combined agent with {gamma}-irradiation and cisplatin treatment in vivo Br. J. Radiol., May 1, 2009; 82(977): 392 - 400. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |